CPT® Code 0340U - Proprietary Laboratory Analyses - AAPC The Current Procedural Terminology (CPT ®) code 0340U as maintained by American Medical Association, is a medical procedural code under the range - Proprietary Laboratory Analyses
CPT® Code 0340U - Coding Ahead Have a question about CPT® Code 0340U? Get instant expert-level answers from CasePilot, our coding assistant
Article - Billing and Coding: MolDX: Minimal Residual Disease Testing . . . For patients with cancer, the UOS for this type of test is 1 Billing should occur at the start of the episode of testing Regarding the use of NGS-based MRD tests (e g , Signatera) in patients with cancer– The service may be performed once per patient per cancer diagnosis, unless there is clinical evidence of a priori change in genetic content
Medical Policy Tumor-Informed Circulating Tumor DNA Testing for Cancer . . . • 0340U: Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient’s tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate
MEDICAL POLICY - PROPRIETARY LABORATORY ANALYSES (PLA) CODES - BCBSM They are alpha-numeric codes consisting of four numbers ending in a capital U They are meant to represent specific laboratory tests developed by a proprietary laboratory The PLA Code section includes Advanced Diagnostic Laboratory Tests (ADLTs) and Clinical Diagnostic Laboratory Tests (CDLTs)
Proprietary Laboratory Analyses (PLA) (prop lab) - Medi-Cal MAAAs are procedures that utilize multiple results derived from assays of various types, including molecular pathology assays, fluorescent in situ hybridization assays and non-nucleic acid-based assays (for example, proteins, polypeptides, lipids, carbohydrates)
EVIDENCE-BASED SOLID TUMOR MINIMAL RESIDUAL DISEASE (MRD) TESTING Minimal residual disease (MRD) analysis (0340U, 0422U, 81479) with sufficient evidence of clinical utility and validity using solid tumor tissue is considered investigational for all other indications where clinical utility and validity have not been demonstrated
CPT® Code 0340U in section: Oncology - Find-A-Code CPT® Vignettes illustrate code use through sample patient examples Every vignette contains a Clinical Example Typical Patient and a description of Procedure Intra-service Where appropriate, there are also Pre- and Post-service descriptions
Current Procedural Coding - OptumCoding 0340U Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient’s tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate